CEL-SCI Corporation

CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and other diseases. The company’s current work centers on immune-based treatments designed to help the body recognize and respond to disease, with research and development spanning oncology, autoimmune conditions, and infectious diseases. Its lead programs include Multikine, an investigational therapy for head and neck cancer, and the LEAPS platform, which supports the creation of targeted immune-modulating candidates. CEL-SCI also combines drug discovery, development, and manufacturing capabilities for complex biological substances, making it a specialized participant in the life sciences sector. Headquartered in Vienna, Virginia, CEL-SCI Corporation operates as a research-driven company within the biotechnology market, where its pipeline is aimed at advancing novel therapeutic approaches through immunology.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Geert R. Kersten Esq.

Headquarters

Vienna, VA, United States

Website

cel-sci.com